Login / Signup

Two-year crizotinib monotherapy induced durable complete response of pediatric ALK-positive inflammatory myofibroblastic tumor.

Akira KainoHidetaka NiizumaSaori KatayamaMasahiro IrieTomohiro NakanoDaichi SatoTsuyoshi SaitoShunsuke KatoYoshiyuki SueharaYoji SasaharaAtsuo Kikuchi
Published in: Pediatric blood & cancer (2023)
Keyphrases
  • advanced non small cell lung cancer
  • high glucose
  • diabetic rats
  • oxidative stress
  • combination therapy
  • endothelial cells
  • drug induced
  • clinical trial
  • randomized controlled trial
  • double blind